<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">Tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor (TNF)-targeted therapies are increasingly used for a rapidly expanding number of rheumatic and <z:hpo ids='HP_0002960'>autoimmune diseases</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>With this use and longer follow-up periods of treatment, there are a growing number of reports of the development of autoimmune processes related to anti-TNF agents </plain></SENT>
<SENT sid="2" pm="."><plain>We have analyzed the clinical characteristics, outcomes, and patterns of association with the different anti-TNF agents used in <z:hpo ids='HP_0000001'>all</z:hpo> reports of <z:hpo ids='HP_0002960'>autoimmune diseases</z:hpo> developing after TNF-targeted therapy found through a MEDLINE search of articles published between January 1990 and December 2006 </plain></SENT>
<SENT sid="3" pm="."><plain>We identified 233 cases of <z:hpo ids='HP_0002960'>autoimmune diseases</z:hpo> (<z:hpo ids='HP_0002633'>vasculitis</z:hpo> in 113, <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> in 92, <z:hpo ids='HP_0006530'>interstitial lung diseases</z:hpo> in 24, and other diseases in 4) secondary to TNF-targeted therapies in 226 patients </plain></SENT>
<SENT sid="4" pm="."><plain>The anti-TNF agents were administered for <z:hpo ids='HP_0001370'>rheumatoid arthritis</z:hpo> (RA) in 187 (83%) patients, <z:e sem="disease" ids="C0010346" disease_type="Disease or Syndrome" abbrv="">Crohn disease</z:e> in 17, <z:e sem="disease" ids="C0038013" disease_type="Disease or Syndrome" abbrv="">ankylosing spondylitis</z:e> in 7, psoriatic <z:hpo ids='HP_0001369'>arthritis</z:hpo> in 6, <z:e sem="disease" ids="C0553662" disease_type="Disease or Syndrome" abbrv="JRA|JIA">juvenile RA</z:e> in 5, and other diseases in 3 </plain></SENT>
<SENT sid="5" pm="."><plain>The anti-TNF agents administered were infliximab in 105 patients, etanercept in 96, adalimumab in 21, and other anti-TNF agents in 3 </plain></SENT>
<SENT sid="6" pm="."><plain>We found 92 reported cases of <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> following anti-TNF therapy (infliximab in 40 cases, etanercept in 37, and adalimumab in 15) </plain></SENT>
<SENT sid="7" pm="."><plain>Nearly half the cases fulfilled 4 or more classification criteria for <z:hpo ids='HP_0002725'>systemic lupus erythematosus</z:hpo> (SLE), which fell to one-third after discarding preexisting <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e>-like features </plain></SENT>
<SENT sid="8" pm="."><plain>One hundred thirteen patients developed <z:hpo ids='HP_0002633'>vasculitis</z:hpo> after receiving anti-TNF agents (etanercept in 59 cases, infliximab in 47, adalimumab in 5, and other agents in 2) </plain></SENT>
<SENT sid="9" pm="."><plain>Leukocytoclastic <z:hpo ids='HP_0002633'>vasculitis</z:hpo> was the most frequent type of <z:hpo ids='HP_0002633'>vasculitis</z:hpo>, and <z:hpo ids='HP_0000979'>purpura</z:hpo> was the most frequent cutaneous lesion </plain></SENT>
<SENT sid="10" pm="."><plain>A significant finding was that one-quarter of patients with <z:hpo ids='HP_0002633'>vasculitis</z:hpo> related to anti-TNF agents had extracutaneous involvement </plain></SENT>
<SENT sid="11" pm="."><plain>Twenty-four cases of <z:hpo ids='HP_0006530'>interstitial lung disease</z:hpo> associated with the use of anti-TNF agents were reported </plain></SENT>
<SENT sid="12" pm="."><plain>In these patients, 2 specific characteristics should be highlighted: the poor prognosis in spite of cessation of anti-TNF therapy, and the possible adjuvant role of concomitant <z:chebi fb="0" ids="44185">methotrexate</z:chebi> </plain></SENT>
<SENT sid="13" pm="."><plain>In conclusion, the use of anti-TNF agents has been associated with an increasing number of cases of <z:hpo ids='HP_0002960'>autoimmune diseases</z:hpo>, principally cutaneous <z:hpo ids='HP_0002633'>vasculitis</z:hpo>, <z:e sem="disease" ids="C0919715" disease_type="Disease or Syndrome" abbrv="">lupus-like syndrome</z:e>, SLE, and <z:hpo ids='HP_0006530'>interstitial lung disease</z:hpo> </plain></SENT>
</text></document>